~~<i id='12F839C34F'><strike id='12F839C34F'><tt id='12F839C34F'><pre id='12F839C34F'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

knowledge

author：comprehensive 2025-09-29 10:31:28 - browse：8

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Will the IRA bring competition to the biologics market?

Wikipedia

focus

hotspot

focus

hotspot

MariaFabrizioforSTATThisstorycontainsdescriptionsofaninvasivemedicalprocedureandmentionofsexualassau

WSS

3 hurdles to bringing medical devices to the U.S. market

New weight loss drugs vying to be the next Wegovy or Mounjaro

FDA approves updated Covid vaccines

The science behind Janet Jackson's pregnancy at 49

Walmart eyes Medicare Advantage provider ChenMed

Death of patient in Alzheimer’s trial raises question of possible risks

explore

knowledge

Wikipedia

After affirmative action ruling, medical educators look to 'holistic review'

WATCH: Why do fingernails fall off when they're damaged?

United colonoscopy coverage change 'may cost lives,' doctors say

Gene therapy has helped boys walk. Can scientists keep it that way?

Alkermes shareholders re

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Hollywood unions extend contract negotiations for actors

Paxlovid study fails to answer questions over benefit for broader groups

The cancer drug shortage isn’t new — and neither are the solutions

How medical schools plan to diversify without affirmative action

focus

Acelyrin, a rare IPO success, stumbles in its first big test

FDA approves updated Covid vaccines

FDA panel endorses Alnylam’s heart drug — after picking it apart

Will the IRA bring competition to the biologics market?

3 hurdles to bringing medical devices to the U.S. market

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

hotspot

focus

focus

hotspot